Showing results (341-350 of 4,634) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|September 1, 1996
Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicitiesR Pazdur, Y Lassere, E Diaz-Canton, et al.
Anti-Cancer Drugs|January 1, 1996
Octreotide therapy in carcinoid diseaseN D Bax, H F Woods, A Batchelor, et al.
Anti-Cancer Drugs|January 1, 1996
Radiolabelled somatostatin analogue scintigraphy in oncologyK J O'Byrne, D N Carney
Anti-Cancer Drugs|June 1, 1996
Comparative in vitro evaluation of dithiane analogs of tiapamil, Ro 11-2933, Ro 44-5911 and Ro 44-5912 as multidrug resistance modulatorsM Abderrabi, S Marchal, J L Merlin
Anti-Cancer Drugs|June 1, 1996
Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in miceM C Bissery, P Vrignaud, F Lavelle, et al.
Anti-Cancer Drugs|June 1, 1996
In vitro synergistic effects of some novel Cu(II) complexes in combination with epirubicin and mitomycin C against HeLa-S3 cervical cancer cell lineG D Geromichalos, G A Katsoulos, C C Hadjikostas, et al.
Anti-Cancer Drugs|June 1, 1996
Metoclopramide as a modulator of cisplatin: effects on pharmacokinetcs and cisplatin-DNA adducts in tumor and normal tissueA Johnsson, E Kjellén, J Wennerberg, et al.
Anti-Cancer Drugs|October 1, 1995
Phase I and pharmacokinetic study of etoposide phosphateD J Brooks, N R Srinivas, D S Alberts, et al.
Anti-Cancer Drugs|October 1, 1995
Pattern of carboplatin-induced emesis. The German Ondansetron Study GroupA du Bois, W Vach, U Cramer-Giraud, et al.
Anti-Cancer Drugs|October 1, 1995
A comparison of the antiemetic efficacy and safety of intramuscular and intravenous formulations of granisetron in patients receiving moderately emetogenic chemotherapyA Contu, N Olmeo, S Piro, et al.
Pageof 464